Your browser doesn't support javascript.
loading
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.
O'Farrell, Marie; Duke, Greg; Crowley, Richard; Buckley, Douglas; Martins, Eduardo B; Bhattacharya, Dipankar; Friedman, Scott L; Kemble, George.
Affiliation
  • O'Farrell M; Sagimet Biosciences Inc., 155 Bovet Rd, San Mateo, CA, 94402, USA. marie.ofarrell@sagimet.com.
  • Duke G; Sagimet Biosciences Inc., 155 Bovet Rd, San Mateo, CA, 94402, USA.
  • Crowley R; Sagimet Biosciences Inc., 155 Bovet Rd, San Mateo, CA, 94402, USA.
  • Buckley D; Sagimet Biosciences Inc., 155 Bovet Rd, San Mateo, CA, 94402, USA.
  • Martins EB; Sagimet Biosciences Inc., 155 Bovet Rd, San Mateo, CA, 94402, USA.
  • Bhattacharya D; Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Friedman SL; Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Kemble G; Sagimet Biosciences Inc., 155 Bovet Rd, San Mateo, CA, 94402, USA.
Sci Rep ; 12(1): 15661, 2022 09 19.
Article in En | MEDLINE | ID: mdl-36123383
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Non-alcoholic Fatty Liver Disease / Liver Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Sci Rep Year: 2022 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Non-alcoholic Fatty Liver Disease / Liver Neoplasms Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Sci Rep Year: 2022 Document type: Article Affiliation country: Country of publication: